Kingmed Diagnostics
Kingmed Diagnostics is a third-party medical inspection service provider.
Kingmed Diagnostics, established in 1994, is a third-party medical inspection and pathological diagnosis service provider, mainly engaging in third-party medical assessment and pathological diagnosis business and providing leading medical diagnosis information integration services and and pathological diagnosis outsourcing services for medical institutions at all levels across the country. Founded by Guangzhou Medical University, it went public in September 2017. Its main shareholder is Liang Yaoming, and peer companies are Transtek Medical Electronics and Inkon Life Technology.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
East China medicine "liraglutide" goes to sea
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Clinical Microbiology Testing Company WillingMed Nets More than 100 Mn in Series B
WillingMed has independently developed and successfully reported and approved a series of automated testing instruments, software, testing reagents and other IVD products, and obtained intellectual property rights for more than 40 core technologies.
Apr 07, 2023 09:09 PM
Jinyu medicine: we are actively cooperating in the investigation of Jinyu incident in Zhengzhou
20 Chinese Companies to Watch in Q1 2023– Healthcare+
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in Q1 2023. The following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, the activity level and the segments in which the startups operate.
Apr 07, 2023 01:39 PM
Gilid signed an agreement with science and technology to deepen strategic cooperation in the areas of chronic hepatitis B, hepatitis C and HIV infection.
Back to Hong Kong, Chinese concept stocks rose collectively, and Wanguo data rose 17.5%